Biotech Ardelyx Beats Shareholder Suit Over Kidney Drug

By Katryna Perera · March 18, 2024, 7:23 PM EDT

Biotechnology company Ardelyx Inc. has for now beaten a shareholder class action alleging the company and its top brass made false and misleading statements about regulatory approval of Ardelyx's drug for...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Order

Case Information

Case Title

Strezsak v. Ardelyx Inc. et al

Case Number

Court

California Northern

Nature of Suit

Securities/Commodities

Date Filed

July 30, 2021

Recent Articles By Katryna

May 02, 2024
Masimo Hit With Derivative Suit Over Audio Co. Acquisition
May 01, 2024
Insulin Pump Maker Wins Toss of Investor Suit For Now
April 30, 2024
Vaxart Investors Want Sanctions Over Deleted Texts
April 08, 2024
Walmart Beats Investor Suit Over Opioid Probe Disclosures
March 29, 2024
Hedge Fund Beats Vaxart Investor's 'Short-Swing' Profits Suit
March 11, 2024
Illumina Brass Faces Shareholder Suit Over Grail Deal Debacle
February 15, 2024
Citadel Securities, Others Beat Biotech Spoofing Suit, For Now
February 06, 2024
Judge Won't Toss All Claims In COVID Test Securities Action
January 29, 2024
Hearing Aid Co. Eargo Investors Ask 9th Circ. To Revive Suit
January 25, 2024
Danaher Execs Face Investor Suit Over Post-Pandemic Slump